R&D Biotech’s biggest challenge isn’t scientific, but political ... We speak to James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy & grandson of FDR
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.